ADT |
androgen deprivation therapy |
AI |
aromatase inhibitors |
ARIC |
Atherosclerosis Risk in Communities |
BMI |
body mass index |
BPA |
bisphenol A |
CEE |
conjugated equine estrogen |
CIMT |
carotid intima-media thickness |
CRP |
C-reactive protein |
CV |
cardiovascular |
CVD |
cardiovascular disease |
CAD |
coronary artery disease |
CHD |
coronary heart disease |
DHEA |
dehydroepiandrosterone |
DHEAS |
dehydroepiandrosterone and its sulfate |
E2 |
estradiol |
GnRH |
gonadotrophin-releasing hormone |
HF |
heart failure |
HDL-C |
high-density lipoprotein cholesterol |
LDL-C |
low-density lipoprotein cholesterol |
MI |
myocardial infarction |
MHT |
menopausal hormone therapy |
MPA |
medroxyprogesterone acetate |
NEN-EN |
norethisterone enanthate |
NHANES |
National Health and Nutrition Examination Surveys |
POC |
progestin-only contraceptive |
RCT |
randomized clinical trial |
SERMs |
selective estrogen receptor modulators |
SWAN |
Study of Women’s Health Across the Nation |
T |
testosterone |
T2D |
type 2 diabetes |
TRT |
testosterone replacement therapy |